{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T11:14:51Z","timestamp":1784200491475,"version":"3.55.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,25]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>This study evaluated the cost-effectiveness of hypofractionated intensity-modulated radiation therapy delivered in 20 fractions (IMRT-20) compared with robot-assisted radical prostatectomy (RARP) for patients with localized low-risk prostate cancer in Japan. A state-transition Markov model was developed from the Japanese healthcare system, using Japanese-specific cost data. Clinical probabilities, adverse event rates and health utility values were primarily derived from international sources, including the ProtecT trial, with extensive sensitivity and scenario analyses to address parameter uncertainty. The base-case analysis compared IMRT-20 and RARP. Scenario analyses included conventional fractionated IMRT (IMRT-38) versus RARP, as well as IMRT-20 versus RARP excluding the utility decrement associated with sexual dysfunction to explore preference-sensitive outcomes. Model outputs included quality-adjusted life-years (QALYs), incremental cost-effectiveness ratios (ICERs) and incremental net monetary benefit (INMB). In the base-case analysis, IMRT-20 yielded a modest QALY gain (0.1164) at slightly higher costs compared with RARP, resulting in an ICER of JPY 143\u2009685 per QALY, well below the Japanese willingness-to-pay threshold of JPY 5\u2009000\u2009000 per QALY. Probabilistic sensitivity analysis showed that IMRT-20 was cost effective in 78.1% of simulations. IMRT-38 was less cost effective because of longer treatment duration and higher resource utilization (ICER JPY 3\u2009317\u2009380 per QALY), although it remained below the threshold. When the disutility of sexual dysfunction was excluded, IMRT-20 was dominated by RARP; however, INMB analysis indicated that IMRT-20 became economically favorable when the disutility exceeded 20%. Overall, IMRT-20 represents a clinically and economically efficient definitive treatment strategy for localized low-risk prostate cancer in Japan, supporting value-based cancer care.<\/jats:p>","DOI":"10.1093\/jrr\/rrag008","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T12:31:46Z","timestamp":1771331506000},"page":"266-275","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness analysis of intensity modulated radiation therapy versus robot-assisted radical prostatectomy for patients with low-risk prostate cancer in Japan"],"prefix":"10.1093","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6307-6916","authenticated-orcid":false,"given":"Ataru","family":"Igarashi","sequence":"first","affiliation":[{"name":"Department of Health Economics and Outcomes Research, Graduate School of Pharmaceutical Sciences, The University of Tokyo , 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8654 ,","place":["Japan"]},{"name":"Department of Health Data Science, Yokohama City University School of Medicine , 3-9-9 Fukuura Kanazawa-ku, Yokohama, Kanagawa 236-0004 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7032-1577","authenticated-orcid":false,"given":"Keiichi","family":"Jingu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Tohoku University Graduate School of Medicine , 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8574 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3348-1969","authenticated-orcid":false,"given":"Kaoru","family":"Ito","sequence":"additional","affiliation":[{"name":"Renagence LLC ., 2-19-44 Takamatsu, Morioka, Iwate, 020-0114 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritsuko","family":"Koba","sequence":"additional","affiliation":[{"name":"Varian Medical Systems, K.K ., 1-11-1 Ohsaki, Shinagawa-ku, Tokyo, 141-0032 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W","family":"Lee","sequence":"additional","affiliation":[{"name":"Varian Medical Systems, Inc ., 801 Pennsylvania Ave, NW Suite 520, Washington, DC, 20004 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"2026071606362295900_ref1","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"key":"2026071606362295900_ref2","first-page":"419","article-title":"Cancer incidence in five continents (CI5) volume XII","volume":"2","author":"Hill","year":"2024","journal-title":"Eur J Cancer Prev"},{"key":"2026071606362295900_ref3","volume-title":"Cancer Statistics in Japan 2023","author":"National Cancer Center Japan"},{"key":"2026071606362295900_ref4","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/iju.15545","article-title":"Japanese clinical practice guidelines for prostate cancer 2023","volume":"31","author":"Kohjimoto","year":"2024","journal-title":"Int J Urol"},{"key":"2026071606362295900_ref5","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1093\/jrr\/rrt049","article-title":"Longitudinal comparison of quality of life after real-time tumor-tracking intensity-modulated radiation therapy and radical prostatectomy in patients with localized prostate cancer","volume":"54","author":"Shinohara","year":"2013","journal-title":"J Radiat Res"},{"key":"2026071606362295900_ref6","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1093\/jjco\/hyp086","article-title":"Five-year follow-up of health-related quality of life after intensity-modulated radiation therapy for prostate cancer","volume":"39","author":"Namiki","year":"2009","journal-title":"Jpn J Clin Oncol"},{"key":"2026071606362295900_ref7","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"2026071606362295900_ref8","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","article-title":"Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer","volume":"35","author":"Catton","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026071606362295900_ref9","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.eururo.2014.02.015","article-title":"Comparative effectiveness of robot-assisted versus open radical prostatectomy cancer control","volume":"66","author":"Hu","year":"2014","journal-title":"Eur Urol"},{"key":"2026071606362295900_ref10","doi-asserted-by":"crossref","first-page":"635","DOI":"10.5980\/jpnjurol.104.635","article-title":"Comparison of initial results with robotic-assisted laparoscopic radical prostatectomy and open retropubic radical prostatectomy","volume":"104","author":"Otsuki","year":"2013","journal-title":"Jpn J Urol"},{"key":"2026071606362295900_ref11","first-page":"625","article-title":"Guideline for economic evaluation of healthcare technologies in Japan","volume":"62","author":"Fukuda","year":"2013","journal-title":"J Natl Inst Public Health"},{"key":"2026071606362295900_ref12","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1186\/s12885-020-07276-4","article-title":"Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial","volume":"20","author":"Sanghera","year":"2020","journal-title":"BMC Cancer"},{"key":"2026071606362295900_ref13","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/s41416-020-0978-4","article-title":"The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer","volume":"123","author":"Noble","year":"2020","journal-title":"Br J Cancer"},{"key":"2026071606362295900_ref14","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.rpor.2017.11.002","article-title":"Treatment outcomes and late toxicities of intensity-modulated radiation therapy for 1091 Japanese patients with localized prostate cancer","volume":"23","author":"Tanaka","year":"2018","journal-title":"Rep Pract Oncol Radiother"},{"key":"2026071606362295900_ref15","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s00345-016-1781-y","article-title":"Intermediate-term cancer control outcomes in prostate cancer patients treated with robotic-assisted laparoscopic radical prostatectomy: a multi-institutional analysis","volume":"34","author":"Abdollah","year":"2016","journal-title":"World J Urol"},{"key":"2026071606362295900_ref16","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/bju.15739","article-title":"Functional and quality of life outcomes of localised prostate cancer treatments (ProtecT study)","volume":"130","author":"Lane","year":"2022","journal-title":"BJU Int"},{"key":"2026071606362295900_ref17","first-page":"e0175866","article-title":"Robotic-assisted vs retropubic radical prostatectomy: a meta-analysis of urinary and sexual recovery","volume":"12","author":"Tang","year":"2017","journal-title":"PLoS One"},{"key":"2026071606362295900_ref18","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.ijrobp.2023.06.209","article-title":"Long-term follow-up analysis of NRG Oncology RTOG 0415: a randomized phase III non-inferiority study comparing two fractionation schedules in patients with favorable-risk prostate cancer","volume":"117","author":"Lee","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026071606362295900_ref19","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.ijrobp.2024.08.012","article-title":"Prostate advanced radiation technologies investigating quality of life (PARTIQoL): phase III randomized clinical trial of proton therapy vs IMRT for localized prostate cancer","volume":"120","author":"Efstathiou","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026071606362295900_ref20","volume-title":"Table of Points of Remuneration for Diagnosis and Treatment April 2024 Edition","author":"Social Insurance Institution"},{"key":"2026071606362295900_ref21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta16410","article-title":"Systematic review and economic modelling of the relative clinical benefit and cost-effectiveness of laparoscopic surgery and robotic surgery for removal of the prostate in men with localised prostate cancer","volume":"16","author":"Ramsay","year":"2012","journal-title":"Health Technol Assess"},{"key":"2026071606362295900_ref22","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision Modelling for Health Economic Evaluation","author":"Briggs","year":"2006"},{"key":"2026071606362295900_ref23","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.jval.2012.06.012","article-title":"Modeling good research practices\u2014overview: a report of the ISPOR-SMDM modeling good research practices task force-1","volume":"15","author":"Caro","year":"2012","journal-title":"Value Health"},{"key":"2026071606362295900_ref24","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1001\/jama.2019.20675","article-title":"Patient-reported outcomes through 5 years for active surveillance, surgery, brachytherapy, or external beam radiation with or without androgen deprivation therapy for localized prostate cancer","volume":"323","author":"Hoffman","year":"2020","journal-title":"JAMA"},{"key":"2026071606362295900_ref25","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13014-016-0689-4","article-title":"Prospective assessment of the quality of life before, during and after image guided intensity modulated radiotherapy for prostate cancer","volume":"11","author":"Sveistrup","year":"2016","journal-title":"Radiat Oncol"},{"key":"2026071606362295900_ref26","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.radonc.2014.03.020","article-title":"A decision model to estimate the cost-effectiveness of intensity modulated radiation therapy compared to three dimensional conformal radiation therapy in patients receiving radiotherapy to the prostate bed","volume":"112","author":"Carter","year":"2014","journal-title":"Radiother Oncol"},{"key":"2026071606362295900_ref27","doi-asserted-by":"publisher","first-page":"e12430","DOI":"10.1111\/ecc.12430","article-title":"Cost-effectiveness analysis of intensity-modulated radiation therapy with normal and hypofractionated schemes for the treatment of localised prostate cancer","volume":"27","author":"Zempl\u00e9nyi","year":"2018","journal-title":"Eur J Cancer Care (Engl)"},{"key":"2026071606362295900_ref28","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","article-title":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from a randomised, open-label, phase 3, non-inferiority trial","volume":"20","author":"Brand","year":"2019","journal-title":"Lancet Oncol"}],"container-title":["Journal of Radiation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jrr\/article-pdf\/67\/2\/266\/67259658\/rrag008.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jrr\/article-pdf\/67\/2\/266\/67259658\/rrag008.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T10:36:29Z","timestamp":1784198189000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jrr\/article\/67\/2\/266\/8509339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,3,6]]},"published-print":{"date-parts":[[2026,3,25]]}},"URL":"https:\/\/doi.org\/10.1093\/jrr\/rrag008","relation":{},"ISSN":["0449-3060","1349-9157"],"issn-type":[{"value":"0449-3060","type":"print"},{"value":"1349-9157","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,3]]}}}